Gotham Asset Management LLC Sells 16,220 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Gotham Asset Management LLC reduced its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 24.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 50,502 shares of the company’s stock after selling 16,220 shares during the quarter. Gotham Asset Management LLC owned approximately 0.09% of Harmony Biosciences worth $1,738,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of HRMY. Hillsdale Investment Management Inc. lifted its position in shares of Harmony Biosciences by 0.4% during the 4th quarter. Hillsdale Investment Management Inc. now owns 68,000 shares of the company’s stock valued at $2,340,000 after acquiring an additional 300 shares during the period. O Shaughnessy Asset Management LLC lifted its position in shares of Harmony Biosciences by 2.1% during the 4th quarter. O Shaughnessy Asset Management LLC now owns 20,450 shares of the company’s stock valued at $704,000 after acquiring an additional 420 shares during the period. PNC Financial Services Group Inc. lifted its position in shares of Harmony Biosciences by 28.7% during the 4th quarter. PNC Financial Services Group Inc. now owns 2,328 shares of the company’s stock valued at $80,000 after acquiring an additional 519 shares during the period. Aviva PLC lifted its position in shares of Harmony Biosciences by 3.9% during the 4th quarter. Aviva PLC now owns 18,072 shares of the company’s stock valued at $622,000 after acquiring an additional 686 shares during the period. Finally, BOKF NA lifted its position in shares of Harmony Biosciences by 4.7% during the 4th quarter. BOKF NA now owns 15,400 shares of the company’s stock valued at $521,000 after acquiring an additional 690 shares during the period. 86.23% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

HRMY has been the topic of a number of research reports. Mizuho boosted their target price on shares of Harmony Biosciences from $44.00 to $48.00 and gave the company an “outperform” rating in a research report on Thursday. Needham & Company LLC restated a “buy” rating and set a $49.00 price objective on shares of Harmony Biosciences in a report on Tuesday, May 6th. Cantor Fitzgerald upgraded shares of Harmony Biosciences to a “strong-buy” rating in a report on Tuesday. HC Wainwright restated a “buy” rating and set a $70.00 price objective on shares of Harmony Biosciences in a report on Tuesday, April 8th. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Harmony Biosciences in a report on Tuesday, February 11th. They set a “buy” rating and a $55.00 price objective on the stock. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $52.78.

Harmony Biosciences Stock Performance

Shares of HRMY stock opened at $35.07 on Friday. The firm has a 50-day moving average of $31.45 and a 200-day moving average of $33.96. The company has a market cap of $2.01 billion, a P/E ratio of 16.62, a P/E/G ratio of 0.47 and a beta of 0.82. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. Harmony Biosciences Holdings, Inc. has a one year low of $26.47 and a one year high of $41.61.

Harmony Biosciences (NASDAQ:HRMY) last announced its earnings results on Tuesday, May 6th. The company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.59 by $0.19. The company had revenue of $184.73 million during the quarter, compared to the consensus estimate of $184.26 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The firm’s revenue for the quarter was up 19.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.67 earnings per share. Equities research analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.